JP2010518160A - 粘膜の疾患による組織の崩壊、傷害又は損傷を治療又は予防する方法 - Google Patents
粘膜の疾患による組織の崩壊、傷害又は損傷を治療又は予防する方法 Download PDFInfo
- Publication number
- JP2010518160A JP2010518160A JP2009549595A JP2009549595A JP2010518160A JP 2010518160 A JP2010518160 A JP 2010518160A JP 2009549595 A JP2009549595 A JP 2009549595A JP 2009549595 A JP2009549595 A JP 2009549595A JP 2010518160 A JP2010518160 A JP 2010518160A
- Authority
- JP
- Japan
- Prior art keywords
- day
- mucositis
- days
- scv
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 30
- 201000010099 disease Diseases 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims description 34
- 230000006378 damage Effects 0.000 title claims description 21
- 208000027418 Wounds and injury Diseases 0.000 title claims description 8
- 208000014674 injury Diseases 0.000 title claims description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 9
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 203
- 201000010927 Mucositis Diseases 0.000 claims description 203
- 108010049353 golotimod Proteins 0.000 claims description 146
- CATMPQFFVNKDEY-YPMHNXCESA-N Golotimod Chemical compound C1=CC=C2C(C[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(O)=O)=CNC2=C1 CATMPQFFVNKDEY-YPMHNXCESA-N 0.000 claims description 142
- 230000005855 radiation Effects 0.000 claims description 85
- 238000011282 treatment Methods 0.000 claims description 81
- 230000037396 body weight Effects 0.000 claims description 35
- 208000025865 Ulcer Diseases 0.000 claims description 27
- 238000001959 radiotherapy Methods 0.000 claims description 17
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 13
- 229960004316 cisplatin Drugs 0.000 claims description 13
- 230000001186 cumulative effect Effects 0.000 claims description 13
- 210000004877 mucosa Anatomy 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 238000002512 chemotherapy Methods 0.000 claims description 11
- -1 heterocyclic amino acid Chemical group 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 230000003902 lesion Effects 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 229930182827 D-tryptophan Chemical group 0.000 claims description 3
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical group C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-Tryptophan Natural products C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 claims description 3
- 108010033276 Peptide Fragments Chemical group 0.000 claims description 3
- 102000007079 Peptide Fragments Human genes 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 229960004799 tryptophan Drugs 0.000 claims description 3
- 101710188315 Protein X Chemical group 0.000 claims description 2
- 230000002411 adverse Effects 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 230000001172 regenerating effect Effects 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 description 142
- 230000009467 reduction Effects 0.000 description 48
- 241000699800 Cricetinae Species 0.000 description 47
- 230000001154 acute effect Effects 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 239000011780 sodium chloride Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 25
- 238000011156 evaluation Methods 0.000 description 23
- 239000003814 drug Substances 0.000 description 22
- 229940079593 drug Drugs 0.000 description 20
- 238000011160 research Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 208000003265 stomatitis Diseases 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 16
- 241000699673 Mesocricetus auratus Species 0.000 description 13
- 231100000419 toxicity Toxicity 0.000 description 13
- 230000001988 toxicity Effects 0.000 description 13
- 239000007929 subcutaneous injection Substances 0.000 description 12
- 238000010254 subcutaneous injection Methods 0.000 description 12
- 229940035676 analgesics Drugs 0.000 description 10
- 239000000730 antalgic agent Substances 0.000 description 10
- 230000036269 ulceration Effects 0.000 description 10
- 230000004584 weight gain Effects 0.000 description 10
- 235000019786 weight gain Nutrition 0.000 description 10
- 208000031648 Body Weight Changes Diseases 0.000 description 8
- 206010040047 Sepsis Diseases 0.000 description 8
- 230000000118 anti-neoplastic effect Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000004579 body weight change Effects 0.000 description 8
- 239000003599 detergent Substances 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 208000031729 Bacteremia Diseases 0.000 description 6
- 238000000546 chi-square test Methods 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 6
- 210000003038 endothelium Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 231100000225 lethality Toxicity 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 210000002200 mouth mucosa Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000003444 anaesthetic effect Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 208000014829 head and neck neoplasm Diseases 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 4
- 206010021033 Hypomenorrhoea Diseases 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 4
- 206010028124 Mucosal ulceration Diseases 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 229940035674 anesthetics Drugs 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000031018 biological processes and functions Effects 0.000 description 4
- 239000007844 bleaching agent Substances 0.000 description 4
- 238000010322 bone marrow transplantation Methods 0.000 description 4
- 239000003560 cancer drug Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000003193 general anesthetic agent Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000003983 inhalation anesthetic agent Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229960003299 ketamine Drugs 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 229960004194 lidocaine Drugs 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000003589 local anesthetic agent Substances 0.000 description 4
- 229960005015 local anesthetics Drugs 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 244000005706 microflora Species 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 231100000683 possible toxicity Toxicity 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002028 premature Effects 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 238000011301 standard therapy Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000007910 systemic administration Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 229960001005 tuberculin Drugs 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 229960001600 xylazine Drugs 0.000 description 4
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 4
- 238000009826 distribution Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000009093 first-line therapy Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 206010018687 Granulocytopenia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000008952 bacterial invasion Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 230000003039 myelosuppressive effect Effects 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 231100000057 systemic toxicity Toxicity 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 125000003164 beta-aspartyl group Chemical group 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- 108010054509 gamma-glutamyltryptophan Proteins 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90097707P | 2007-02-13 | 2007-02-13 | |
| PCT/US2008/001768 WO2008100458A2 (en) | 2007-02-13 | 2008-02-11 | Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010518160A true JP2010518160A (ja) | 2010-05-27 |
| JP2010518160A5 JP2010518160A5 (OSRAM) | 2011-04-07 |
Family
ID=39690681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549595A Withdrawn JP2010518160A (ja) | 2007-02-13 | 2008-02-11 | 粘膜の疾患による組織の崩壊、傷害又は損傷を治療又は予防する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7906486B2 (OSRAM) |
| EP (1) | EP2120986A4 (OSRAM) |
| JP (1) | JP2010518160A (OSRAM) |
| KR (1) | KR20090119897A (OSRAM) |
| CN (1) | CN101657210A (OSRAM) |
| AR (1) | AR065338A1 (OSRAM) |
| AU (1) | AU2008216799A1 (OSRAM) |
| CA (1) | CA2677749A1 (OSRAM) |
| IL (1) | IL200364A0 (OSRAM) |
| MX (1) | MX2009008641A (OSRAM) |
| NZ (1) | NZ579570A (OSRAM) |
| TW (1) | TW200845958A (OSRAM) |
| UA (1) | UA96980C2 (OSRAM) |
| WO (1) | WO2008100458A2 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2677749A1 (en) * | 2007-02-13 | 2008-08-21 | Sciclone Pharmaceuticals, Inc. | Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa |
| RU2436587C1 (ru) * | 2010-10-21 | 2011-12-20 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | N-изовалероил-l-глутамил-l-триптофан как средство, препятствующее язвообразованию в желудке и двенадцатиперстной кишке |
| CN109528202B (zh) * | 2018-11-14 | 2021-07-16 | 北京大学第一医院 | 一种头颈部放疗诊疗系统 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4125626A (en) * | 1977-01-17 | 1978-11-14 | Mt. Sinai School Of Medicine Of The City University Of New York | Synthesis and use of L-γ-glutamyl-DOPA |
| US4568489A (en) * | 1984-06-29 | 1986-02-04 | E. R. Squibb & Sons, Inc. | N-Acyl-γ-glutamyl imino and amino acids and esters |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4758551A (en) * | 1986-07-08 | 1988-07-19 | Cornell Research Foundation, Inc. | Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types |
| US4968672A (en) * | 1987-01-02 | 1990-11-06 | The United States Of America As Represented By The Department Of Health And Human Services | Adenosine receptor prodrugs |
| US4895835A (en) * | 1987-11-20 | 1990-01-23 | Nisshin Oil Mills, Ltd. | Muramyl peptide derivatives and use thereof |
| US5728680A (en) * | 1987-12-30 | 1998-03-17 | Cytoven J.V. | Methods for normalizing numbers of lymphocytes |
| US5902790A (en) * | 1995-10-03 | 1999-05-11 | Cytran, Inc. | Pharmaceutical angiostatic dipeptide compositions and method of use thereof |
| US5206220A (en) * | 1990-04-23 | 1993-04-27 | Research Corporation Technologies, Inc. | Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition |
| WO1992017191A1 (en) | 1991-04-01 | 1992-10-15 | Cytoven | Pharmaceutical dipeptide compositions and methods of use thereof |
| WO1993008815A1 (en) | 1991-10-28 | 1993-05-13 | Cytoven | Pharmaceutical dipeptide compositions and methods of use thereof |
| WO1994020063A2 (en) | 1993-03-04 | 1994-09-15 | Cytoven International N.V. | Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof |
| GB9320820D0 (en) * | 1993-10-08 | 1993-12-01 | Biokine Tech Ltd | Compounds for medicinal use |
| RU2107692C1 (ru) * | 1995-06-07 | 1998-03-27 | Дейгин Владислав Исакович | Пептид и способ его получения |
| US5888980A (en) * | 1994-06-30 | 1999-03-30 | Bio-Logic Research And Development Corporation | Compositions for enhancing immune function |
| US5916878A (en) * | 1995-11-28 | 1999-06-29 | Edward T. Wei | γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith |
| US5744452A (en) * | 1995-11-28 | 1998-04-28 | Edward T. Wei | γ-L-glutamyl containing immunomodulator compounds and methods therewith |
| RU2120298C1 (ru) | 1995-11-28 | 1998-10-20 | Товарищество с ограниченной ответственностью "Верта" | Иммуностимулятор и препарат на его основе |
| WO1997019691A1 (en) | 1995-11-28 | 1997-06-05 | Wei, Edward, T. | Gamma-l-glutamyl containing immunomodulator compounds and methods therewith |
| US6060452A (en) * | 1996-03-13 | 2000-05-09 | Cytran, Inc. | Analogs of L-Glu-L-Trp having pharmacological activity |
| RU2141483C1 (ru) | 1997-07-04 | 1999-11-20 | Небольсин Владимир Евгеньевич | Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция |
| US7173013B2 (en) * | 2001-06-08 | 2007-02-06 | Sciclone Pharmaceuticals, Inc. | Treatment of tuberculosis using immunomodulator compounds |
| RU2229892C2 (ru) | 2001-06-08 | 2004-06-10 | Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" | Способ лечения туберкулеза легких |
| US20050256042A1 (en) * | 2003-05-09 | 2005-11-17 | Jeffers Michael E | Methods of preventing and treating alimentary mucositis |
| AU2005244826B2 (en) * | 2004-05-14 | 2010-07-29 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of respiratory viral infections with immunomodulator compounds |
| JP4874985B2 (ja) | 2004-10-27 | 2012-02-15 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | 免疫調節化合物による出血性ウイルス感染の治療又は予防 |
| WO2006076169A2 (en) | 2004-12-28 | 2006-07-20 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of genital viral infections with immunomodulator compounds |
| US20090074815A1 (en) * | 2005-04-22 | 2009-03-19 | Sciclone Pharmaceuticals, Inc. | Immunomodulator Compounds as Vaccine Enhancers |
| AU2007240946A1 (en) * | 2006-04-20 | 2007-11-01 | Sciclone Pharmaceuticals, Inc. | Treatment of melanoma |
| JP2010513508A (ja) | 2006-12-18 | 2010-04-30 | アキリオン ファーマシューティカルズ，インコーポレーテッド | Ｃ型肝炎感染を処置するための併用療法 |
| CA2677749A1 (en) * | 2007-02-13 | 2008-08-21 | Sciclone Pharmaceuticals, Inc. | Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa |
| RU2007118237A (ru) | 2007-05-17 | 2008-11-27 | ООО "Научно-производственна фирма Верта" (RU) | Способ лечения аллергических заболеваний |
| US20110189305A1 (en) | 2007-08-23 | 2011-08-04 | Tuthill Cynthia W | Treatment of lung cancer |
| JP2011530519A (ja) | 2008-08-06 | 2011-12-22 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | 免疫調節化合物を用いたｃ型肝炎の治療または予防の方法 |
-
2008
- 2008-02-11 CA CA002677749A patent/CA2677749A1/en not_active Abandoned
- 2008-02-11 US US12/526,585 patent/US7906486B2/en not_active Expired - Fee Related
- 2008-02-11 KR KR1020097018913A patent/KR20090119897A/ko not_active Withdrawn
- 2008-02-11 EP EP08725404A patent/EP2120986A4/en not_active Withdrawn
- 2008-02-11 MX MX2009008641A patent/MX2009008641A/es not_active Application Discontinuation
- 2008-02-11 UA UAA200909229A patent/UA96980C2/ru unknown
- 2008-02-11 NZ NZ579570A patent/NZ579570A/en not_active IP Right Cessation
- 2008-02-11 CN CN200880011935A patent/CN101657210A/zh active Pending
- 2008-02-11 JP JP2009549595A patent/JP2010518160A/ja not_active Withdrawn
- 2008-02-11 AU AU2008216799A patent/AU2008216799A1/en not_active Abandoned
- 2008-02-11 WO PCT/US2008/001768 patent/WO2008100458A2/en not_active Ceased
- 2008-02-13 AR ARP080100621A patent/AR065338A1/es not_active Application Discontinuation
- 2008-02-13 TW TW097105084A patent/TW200845958A/zh unknown
-
2009
- 2009-08-12 IL IL200364A patent/IL200364A0/en unknown
-
2011
- 2011-01-25 US US13/013,340 patent/US20110117211A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ579570A (en) | 2012-02-24 |
| EP2120986A4 (en) | 2010-04-07 |
| CA2677749A1 (en) | 2008-08-21 |
| KR20090119897A (ko) | 2009-11-20 |
| US20100086622A1 (en) | 2010-04-08 |
| WO2008100458A2 (en) | 2008-08-21 |
| AU2008216799A1 (en) | 2008-08-21 |
| MX2009008641A (es) | 2009-09-14 |
| EP2120986A2 (en) | 2009-11-25 |
| UA96980C2 (ru) | 2011-12-26 |
| IL200364A0 (en) | 2010-04-29 |
| TW200845958A (en) | 2008-12-01 |
| CN101657210A (zh) | 2010-02-24 |
| US7906486B2 (en) | 2011-03-15 |
| AR065338A1 (es) | 2009-06-03 |
| WO2008100458A3 (en) | 2008-11-27 |
| US20110117211A1 (en) | 2011-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115645388B (zh) | 氨基酸组合物及其用途 | |
| EP3842047B1 (en) | High elasticity hyaluronan compositions and methods of use thereof | |
| US10272063B2 (en) | Treatment for ischemic stroke | |
| WO1991002529A2 (en) | Product and method for killing abnormal vertebrate cells | |
| JP5030553B2 (ja) | ドライマウスおよび／または唾液分泌障害を処置するための医薬 | |
| WO2020015731A1 (zh) | 亚砜类化合物在预防放射性口腔黏膜炎及相关放疗并发症中的用途 | |
| JP2010518160A (ja) | 粘膜の疾患による組織の崩壊、傷害又は損傷を治療又は予防する方法 | |
| US20090088392A1 (en) | Treatment of melanoma | |
| US11918621B2 (en) | Methods and treatments using toll-like receptor agonists to mitigate hematopoietic myeloid loss, increase gastrointestinal recovery and reduce tumor growth | |
| WO2017173308A1 (en) | Radiation mitigator and method of use thereof | |
| JPWO2006043336A1 (ja) | 胃粘膜疾患の治療又は予防のための組成物 | |
| KR20050086819A (ko) | 알파 티모신을 사용한 방사능 손상에 대한 보호방법 | |
| EP3827821B1 (en) | Use of pharmaceutical composition to treat epilepsy seizure and/or to treat epilepsy associated motor symptom and cognitive impairment | |
| ES2316977T3 (es) | Uso de un antagonista de adrenorreceptor alfa2 para el tratamiento de la epilepsia. | |
| CN101842009A (zh) | 肺癌的治疗 | |
| JP6099043B2 (ja) | 造血又は腸管放射線障害防護剤 | |
| WO2023239842A1 (en) | Beta carbolines as topical anti-inflammatory agents for application to mucous membranes | |
| CA3212601A1 (en) | Specialized pro-resolving mediators (spms) as melanocyte growth promoter and pro-survival factors and uses thereof | |
| CN111789951A (zh) | 预防恐惧记忆和其相关疾病的方法和药物组合物 | |
| TW202515897A (zh) | 溶瘤肽及其用途 | |
| UA129420C2 (uk) | Стоматологічний гель | |
| KR20090035279A (ko) | 위장관 손상 예방 및 치료용 조성물 | |
| JP2011506473A (ja) | キナーゼ阻害剤と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| JPH07503968A (ja) | ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンの浮腫および痛みの治療のための使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110214 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110214 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20130125 |